Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.

Bibliographic Details
Main Authors:	Qian Li, Mei Liu, Fei Ma, Yang Luo, Ruigang Cai, Liming Wang, Ningzhi Xu, Binghe Xu
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4549142?pdf=render

id	doaj-67104f40c2ac4cacbc6ff775388937f2
record_format	Article
spelling	doaj-67104f40c2ac4cacbc6ff775388937f22020-11-25T02:22:52ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01108e013682610.1371/journal.pone.0136826Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.Qian LiMei LiuFei MaYang LuoRuigang CaiLiming WangNingzhi XuBinghe Xuhttp://europepmc.org/articles/PMC4549142?pdf=render
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Qian Li Mei Liu Fei Ma Yang Luo Ruigang Cai Liming Wang Ningzhi Xu Binghe Xu
spellingShingle	Qian Li Mei Liu Fei Ma Yang Luo Ruigang Cai Liming Wang Ningzhi Xu Binghe Xu Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel. PLoS ONE
author_facet	Qian Li Mei Liu Fei Ma Yang Luo Ruigang Cai Liming Wang Ningzhi Xu Binghe Xu
author_sort	Qian Li
title	Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.
title_short	Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.
title_full	Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.
title_fullStr	Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.
title_full_unstemmed	Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.
title_sort	correction: circulating mir-19a and mir-205 in serum may predict the sensitivity of luminal a subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.
publisher	Public Library of Science (PLoS)
series	PLoS ONE
issn	1932-6203
publishDate	2015-01-01
url	http://europepmc.org/articles/PMC4549142?pdf=render
work_keys_str_mv	AT qianli correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel AT meiliu correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel AT feima correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel AT yangluo correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel AT ruigangcai correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel AT limingwang correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel AT ningzhixu correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel AT binghexu correctioncirculatingmir19aandmir205inserummaypredictthesensitivityofluminalasubtypeofbreastcancerpatientstoneoadjuvantchemotherapywithepirubicinpluspaclitaxel
_version_	1724861479999504384

Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel.

Similar Items